Vycor Medical reported annual revenue growth of 17% to $1.86 million for 2025, achieving an operating profit of $33,900 compared to a loss in 2024, driven by strong international sales of its neurosurgical device.
Key takeaways
Revenue increased 17% to $1.86 million in 2025, with the Vycor Medical division growing 18% primarily from international markets.
The company achieved GAAP operating profit of $33,900, reversing a $9,145 loss in 2024, while non-GAAP operating profit was $145,881.
Gross margin declined to 83% from 89% due to validation, shipping, higher manufacturing costs, and increased international sales mix.
Seven new peer-reviewed studies on the ViewSite Brain Access System were published in 2025, bringing total clinical papers to 50.
A new study validated NovaVision's NeuroEyeCoach therapy as equally effective in home and clinic settings, supporting digital healthcare trends.